Batyrbek Assembekov

Dr. Batyrbek Assembekov


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
DDDimash Davletov
Dimash Davletov
Mukhtar KulimbetMukhtar Kulimbet
Mukhtar Kulimbet
AMAlisher Makhmutov
Alisher Makhmutov
DODinmukhammed Osser
Dinmukhammed Osser
MPMarat Pashimov
Marat Pashimov
KDKairat Davletov
Kairat Davletov
Ischemic heart disease (IHD) remains a leading cause of death globally. This study aims to analyze the burden of IHD in Central Asia and in individual countries of the region from 1990 to 2021, through a comparison of trends in incidence, prevalence, mortality, and disability-adjusted life years. Using data from the Global Burden of Disease (GBD) 2021 study, we extracted annual estimates for the Central Asian region, Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, Turkmenistan, Georgia, Armenia, Azerbaijan, and Mongolia. Metrics were reported as age-standardized rates per 100,000 population. Temporal trends were quantified using Average Annual Percent Change based on joinpoint regression models. A stratification by sex and age groups was done. Central Asia consistently maintained a higher IHD burden than the global average. While global age-standardized incidence rates per 100,000 population fell, Central Asia’s rates per 100,000 population rose from 641.97 in 1990 to 801.56 in 2021. Age-standardized death rates per 100,000 population in the region peaked in the mid-1990s following the dissolution of the Soviet Union but decreased overall from 320.47 in 1990 to 265.51 in 2021. However, this remains significantly higher than the 2021 global rate per 100,000 population of 108.73. Uzbekistan exhibited the highest growth in prevalence and incidence rates per 100,000 population, while Georgia demonstrated the largest reduction in DALYs rates per 100,000 population. Men demonstrated a higher burden across most metrics, although the sex gap narrowed in older populations. Central Asia faces rising incidence rates of IHD and burden levels that far exceed global averages. The significant heterogeneity among countries suggests that region-wide generalizations are insufficient and highlights the critical need for targeted, country-specific prevention programs and health system interventions.

27 July 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
KDKairat Davletov
Kairat Davletov
DDDimash Davletov
Dimash Davletov
BZBekbolat Zholdin
Bekbolat Zholdin
Mukhtar KulimbetMukhtar Kulimbet
Mukhtar Kulimbet
DODinmukhammed Osser
Dinmukhammed Osser
BABatyrbek Assembekov
Batyrbek Assembekov
Background: Poor sleep quality is an increasingly recognized, modifiable cardiovascular risk factor, yet data among patients with established coronary heart disease (CHD) in Central Asia are scarce. We estimated the prevalence of poor sleep quality and identified its correlates in a Kazakhstani CHD population. Methods: In this multi-center cross-sectional study, 398 patients 6–24 months after an index coronary event were assessed for sleep quality. Sleep quality was measured with the Pittsburgh Sleep Quality Index (PSQI; >5 = poor). Anxiety and depression, physical activity, cognition, and clinical and socio-demographic variables were recorded. Associations were examined using logistic regression with subgroup and interaction analyses. Results: Poor sleep quality was reported by 147 patients (36.9%). In the adjusted model, anxiety was the only independent factor associated with poor sleep (OR 1.88, 95% CI: 1.10 to 3.23). The subgroup analysis suggested anxiety (OR 3.94) and lower education (OR 2.58) as correlates in women, whereas retirement (OR 2.27) and low physical activity (OR 2.31) were linked to poor sleep in men. A significant sex–anxiety interaction demonstrated a weaker anxiety effect in men. Conclusions: More than one-third of CHD patients reported poor sleep quality, driven primarily by anxiety, with distinct sex- and age-specific determinants. Sleep and psychological screening should be integrated into secondary prevention, with personalized approaches.

KDKairat Davletov
Kairat Davletov
DDDimash Davletov
Dimash Davletov
BZBekbolat Zholdin
Bekbolat Zholdin
GKGulnara Kurmanalina
Gulnara Kurmanalina
VMVadim Medovchshikov
Vadim Medovchshikov
BABatyrbek Assembekov
Batyrbek Assembekov
Background: Physical activity (PA) is central to the secondary prevention of coronary heart disease (CHD), yet real-world adherence is poor, and data from Central Asia are scarce. Methods: In this cross-sectional study (October 2024–May 2025), 402 patients were recruited 6–24 months after an index coronary event at two Kazakh centers. PA was measured by IPAQ-SF and dichotomized as low versus moderate/high IPAQ-SF category. Multivariable logistic regression identified independent associations with low PA. Results: A total of 152 patients (37.8%) had low PA. Activity was almost exclusively ambulatory: 86.3% reported walking but only 19.9% had any moderate and 11.7% any vigorous activity, and only 29 (7.2%) met WHO/ESC recommendations without counting walking. Low PA was independently associated with recruitment in Aktobe (aOR 3.76, 95% CI 1.98–7.34) and obesity (aOR 1.68, 1.04–2.69); professional exercise advice (aOR 0.45, 0.27–0.73) and the absence of depressive symptoms (aOR 0.42, 0.23–0.76) were associated with lower odds of low PA. Advice was often given but inconsistently followed, and the uptake of fitness clubs (5.6%) and walking groups (10.8%) was minimal. Conclusions: More than one in three patients had low PA, and fewer than one in ten met WHO/ESC recommendations when excluding walking. Depression, obesity, and regional disparity and not conventional risk factors characterized inactive patients.

BSBolat Sadykov
Bolat Sadykov
AAAltyn Aringazina
Altyn Aringazina
ASAlmaz Sharman
Almaz Sharman
ASAkkumis Salkhanova
Akkumis Salkhanova
ASAigul Sharipbayeva
Aigul Sharipbayeva
IFIldar Fakhradiyev
Ildar Fakhradiyev
Published household statistics describe food quantities and budget allocation but do not directly measure individual dietary intake. This study examined food-group-specific socioeconomic and household-composition contrasts and food-purchase expenditure distributions in Kazakhstan in 2025. An ecological repeated cross-sectional study used official household survey aggregates. Regional maps reproduced published fruit and fish indicators for 2025. Recent regional urban–rural comparisons covered 2022–2025, with the principal interpretation restricted to 11 oblasts not involved in the 2022 regional splits; six oblasts with estimated 2022 values were displayed separately. The national annual series for 2001–2025 was retained as historical context rather than a fully harmonised estimate of dietary change. In 2025, the highest population decile of per capita income used for consumption had a fish indicator 3.9 times that of the lowest decile; corresponding ratios were approximately 3.3 for meat, milk/dairy products and fruit and 1.5 for bread/cereal products. Per capita indicators were lower across all ten food groups in households with five or more members than in one-person households. Food purchases exceeded 50% of consumer expenditure in 64.0% of households and 71.7% of households with five or more children. Recent regional changes differed by food group and urban–rural category. These descriptive findings identify contrasts in household apparent consumption and expenditure allocation. They do not establish individual dietary adequacy, food-insecurity prevalence, household-level associations between separately tabulated indicators, or independent causal effects.

16 October 2026 in Life
Verified
Journal Article
Open access
PDF file
BSBolat Sadykov
Bolat Sadykov
ABAbay Baigenzhin
Abay Baigenzhin
AGAnastasia Ganina
Anastasia Ganina
MKMadina Karimova
Madina Karimova
AAAizhan Akhaeva
Aizhan Akhaeva
IFIldar Fakhradiyev
Ildar Fakhradiyev
The manufacturing of placenta- and umbilical cord-derived mesenchymal stromal cells (MSCs) varies across anatomical starting material, isolation, culture supplementation, expansion, scale-up, cryopreservation, and release testing. This variability limits comparability between products and complicates process transfer. The study aimed to map full-text evidence on manufacturing variables, process outcomes, candidate critical material attributes (CMAs), candidate critical process parameters (CPPs), critical quality attributes (CQAs), potency assays, and release strategies for human placenta- and umbilical cord-derived MSCs. A systematic scoping review was conducted using a Population–Concept–Context framework and reported according to PRISMA-ScR, with search reporting guided by PRISMA-S. Searches without publication-date restrictions were completed on 15 August 2026. Two reviewers independently screened records and full texts, and charted data were independently verified. Findings were mapped by manufacturing contrast and outcome domain; quantitative pooling was considered only when biological, process, and methodological comparability supported an interpretable common effect estimate. The primary Scopus/Web of Science search identified 18,860 records; 13,122 unique records were screened and 439 full-text reports were assessed. After 208 exclusions, 231 manufacturing reports remained; the PubMed/MEDLINE search and backward/forward citation searching contributed two and five additional unique eligible reports, respectively, after cross-source deduplication, yielding 238 included reports. The study-family sensitivity set contained 236 distinct study families after linked-report assessment. Tissue-source coding identified 183 umbilical cord/Wharton’s jelly reports, 46 placental reports, and nine multi-source perinatal reports. The most frequent domains were expansion/passaging/senescence (94/238; 39.5%), media/supplements (69; 29.0%), isolation/tissue processing (67; 28.2%), and GMP/quality/release (48; 20.2%). Direct-comparison sets included 2D versus 3D/bioreactor expansion (23 reports), explant versus enzymatic isolation (22), fresh/native versus cryopreserved material (19), HPL versus FBS (12), and hypoxia versus normoxia (10). Differences in intervention definition, tissue compartment, passage/timepoint, endpoint, and unit did not support a coherent common pooled effect. The mapped evidence supports an end-to-end development model and does not identify a universal manufacturing recipe. Anatomical starting material, isolation, culture conditions, cumulative population doublings, scale-up, cryopreservation, and potency-linked release should be treated as interdependent elements of product comparability. Formal designation of CMAs and CPPs remains product- and platform-specific and requires evidence that links process variation to relevant CQAs.